LOTTE Biologics is embarking on an ambitious journey as it fortifies its commitment to quality across its biomanufacturing sites in Syracuse, New York, and Songdo, South Korea. With the rollout of a new single-use antibody-drug conjugate (ADC) facility, LOTTE is implementing a culture that prioritizes quality through comprehensive training, diligent self-audits, and continuous regulatory monitoring.
The company has set its sights on 2026 as a milestone year, aiming not only to strengthen its quality culture but also to advance the development of its Bio Campus in Songdo. This dual focus underscores the organization’s commitment to establishing a cohesive global operational framework.
Fostering a Quality-First Culture
Emily Yourd, the Associate Director of Quality Assurance Compliance at LOTTE Biologics, emphasizes the company’s forward-thinking approach. The goal is to cultivate a culture where quality is ingrained in every aspect of the organization.
“2026 is shaping up to be an exciting year for LOTTE Biologics,” Yourd shared in a recent interview. The continuous enhancement of its quality culture aligns closely with activities at the Syracuse Bio Campus while fostering collaboration with Korean counterparts to prepare the new facility in Songdo.
Strategic Contamination Control
LOTTE Biologics is deploying a systematic strategy for contamination control that is detailed in a comprehensive document outlining its guiding principles. This strategy is especially relevant to the design of facilities and equipment. Wherever feasible, the organization utilizes closed and functionally closed systems, complemented by validated cleaning protocols to mitigate risks of contamination.
The ADC facility is designed around single-use technologies, further reducing the likelihood of cross-contamination. By leveraging these advanced systems, LOTTE Biologics is setting a high standard for operational integrity.
Operational Excellence Through Rigorous Protocols
Beyond engineering controls, the company emphasizes operational protocols and monitoring to enhance safety and compliance. This includes meticulous cleaning and product changeover processes, gowning practices, and material flow protocols, all reinforced by a robust training program for personnel.
Yourd notes, “Through these various factors, we ensure that risks are identified and controlled before they can impact product quality or patient safety.” This proactive mindset is essential for maintaining high standards in biomanufacturing.
Preparedness for Regulatory Scrutiny
LOTTE Biologics is poised for regulatory inspections, whether scheduled or spontaneous. Yourd highlights that the staff takes immense pride in their work environments, cultivating a sense of ownership that empowers employees to identify and address potential issues proactively.
The company has instituted a thorough internal inspection process, with management conducting regular walk-throughs to verify that operations are maintained in a controlled state. This auditing process also includes cross-functional team members to provide diverse perspectives, minimizing the risk of complacency.
Vigilance in Regulatory Compliance
In conjunction with internal audits, LOTTE Biologics maintains a dedicated team focused on regulatory and compendium surveillance. This group, comprising scientists and quality assurance professionals, tracks global regulatory trends and upcoming guidance updates, ensuring that the organization remains compliant with evolving standards.
This vigilant approach allows LOTTE Biologics to assess the potential impacts of regulatory changes on its operations promptly, facilitating timely adjustments. With products distributed in over 60 countries, the company’s commitment to compliance is paramount.
Client Engagement and Transparency
LOTTE Biologics values transparency and collaboration with its clients. Regular plant visits are encouraged, and scheduled meetings ensure that clients remain informed about project statuses. This level of communication fosters trust and enables timely decision-making when necessary.
Yourd emphasizes the importance of these interactions, stating, “We want to keep our clients updated so we can make informed decisions together.” This collaborative spirit is integral to the company’s operational philosophy.
Conclusion
As LOTTE Biologics prepares for its ambitious goals in 2026, its unwavering focus on quality control positions it as a leader in the biologics sector. By fostering a culture of proactive engagement and continuous improvement, the company not only enhances its operational integrity but also reinforces its commitment to patient safety and product excellence. The future looks promising for LOTTE Biologics as it navigates the complex landscape of biomanufacturing with confidence.
- LOTTE Biologics is enhancing its quality culture ahead of a new ADC facility launch in 2026.
- A systematic approach to contamination control is central to the company’s operational strategy.
- Regular internal audits and cross-functional reviews help maintain high standards and accountability.
- Client engagement is prioritized through transparent communication and opportunities for plant visits.
- LOTTE Biologics actively monitors global regulatory trends to ensure compliance and adapt to changes.
Read more → www.biospace.com